# Urotronic

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/urotronic

- Industry: Medical Devices & Equipment
- Headquarters: Plymouth, US
- Website: www.urotronic.com
- Total disclosed funding: $20M
- Latest round: Series B (Aug 20, 2018)
- Investors on record: 4

## About

Based in Minnesota, US, and founded in 2015, Urotronic, Inc. operates as a medical device company that develops a drug-coated balloon (DCB) called Optilume used for the treatment and prevention of recurrence of urethral stricture. In January 2022, Laborie, Inc., a portfolio company of Investor AB, acquired Urotronic, Inc. from CD Capital, Hillhouse Capital Group, Legend Capital, and Mayo Clinic Ventures.

Urotronic provides optilume, which is a urethral drug-coated balloon used as an alternative to endoscopic stricture treatments for male anterior urethral strictures that offers immediate relief.

## Funding rounds

- Series B, Aug 20, 2018, $20M — Mayo Clinic Ventures, Legend Capital, Hillhouse Investment, CD Capital

## Investors

- Mayo Clinic Ventures (https://capitalatlas.ai/funds/mayo-clinic-ventures) — Series B
- Legend Capital — Series B
- Hillhouse Investment (https://capitalatlas.ai/funds/hillhouse-investment) — Series B
- CD Capital — Series B